Abstract:Background: Steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) significantly affect children's quality of life. There are frequent relapses in SSNS and progression in SRNS. IPNA guidelines suggest that monoclonal antibodies like rituximab (RTX) are promising treatments. Objective: This study aims to evaluate the long-term efficacy and safety of rituximab administration in children with SSNS, encompassing FRNS and SDNS, and SRNS over a two-year follow-up period, facilitating individualized management. Methods: We conducted an open-label, multicenter, randomized, and patient-oriented study (RICHNESS), involving children aged 3–18 with SRNS (18) and SSNS (11) undergoing 2 years continuous RTX therapy. The primary outcome was complete/partial remission (CR/PR), as defined by IPNA/KDIGO guidelines, at 6, 12, 18, and 24 months on RTX; secondary outcomes included adverse events. Key endpoints included the estimated glomerular filtration rate (eGFR), the albumin-to-creatinine ratio (ACR), CD20 levels, IgG levels, and the incidence of infections. Kidney biopsies were performed in 94% of SRNS patients. RTX was administered every 6–9 months, depending on CD20 levels, IgG levels, and the presence of infections. The eGFR and ACR were assessed every 6 months. Results: Some 31 children were selected for RTX treatment. Overall, 2 experienced severe allergic reactions, leading to their exclusion from the final analysis of 29 children. In the SSNS group, all children achieved and maintained complete remission within 2 years. Remission rates in the SRNS group ranged from 39% (RR 0.78; 95% CI: 16.4–61.4%, NNT 9) at the 6th month to 72% (RR 1.44; 95% CI: 51.5–92.9%) over the 2-year follow-up period due to continuous RTX therapy. The median duration of RTX use was 26.1 months, with a median cumulative dose of 1820 mg/m2. Adverse reactions and complications were presented by mild infusion-related reactions in 3 children (10.3%), severe allergic reactions in 2 children (6.2%), hypogammaglobulinemia in 7 children (24%), infections in 3 children (10.3%), severe destructive pneumonia in 1 child, recurrent respiratory infections in 2 children, and neutropenia in 1 child (3.44%). Conclusions: RTX was tolerated well, and proved highly effective as a steroid-sparing agent, offering potential in terms of stopping relapses and minimizing steroid-related side effects. It also demonstrated efficacy in slowing progression in SRNS, indicating potential for use in ACR reduction and renal function restoration, but requires careful use given potential severe allergic reactions and infectious complications. Further studies should focus on long-term cost-effectiveness and deferred side effects.

Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome

The case of Kawasaki disease after rituximab infusion triggered by human anti-chimeric antibodies

Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up

Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome

Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature

Rituximab in childhood steroid-sensitive nephrotic syndrome: are multiple subsequent courses safe and effective?

Single Dose of Rituximab in Children with Steroid-Dependent Minimal Change Nephrotic Syndrome

Efficacy and safety of Rituximab in the treatment of refractory steroid-resistant nephrotic syndrome

Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome

Rituximab for nephrotic syndrome in children

Rituximab Use in the Management of Childhood Nephrotic Syndrome

Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth

Efficacy of Rituximab Therapy in Children with Refractory Nephrotic Syndrome: a Prospective Observational Study in Shanghai

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome

Long－term Observation of RituXimab Therapy for Children with Frequently Relapsing Nephrotic Syndrome

Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.

Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey

The Efficacy and Safety of Rituximab for Childhood Steroid-Dependent Nephrotic Syndrome: A Systematic Review and Meta-Analysis

Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis

Early Rituximab As an Add-On Therapy in Children with the Initial Episode of Nephrotic Syndrome